RxDoctor Payments Data

Jennifer Rice, MD

Family Medicine · Buffalo, WYNPI 1336229624

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.

$652in general payments, 2019–2025

Across 32 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138
  • Novo Nordisk$95
  • Amgen$64
  • GSK$50
  • Novartis$38
  • AstraZeneca$36
  • plus $230 from 10 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$652 in reported general payments places this provider in the 75th percentile of 237 family medicine providers in Wyoming.

See all family medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$7,287
Medicare patients
39
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$46,489
OzempicSemaglutide36$35,996
TrulicityDulaglutide26$28,113
Praluent PenAlirocumab25$12,406
JardianceEmpagliflozin11$11,191
Breo ElliptaFluticasone/Vilanterol15$9,784
Levothyroxine Sodium295$4,559
Celecoxib50$4,105
Losartan Potassium176$2,830
Omeprazole122$2,451
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,379
SynthroidLevothyroxine Sodium20$2,263
Metoprolol Succinate105$2,255
Estradiol29$2,071
Atorvastatin Calcium174$2,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$46,48935 claims
Novo NordiskOzempic$95$35,99636 claims
Lilly USA, LLCTrulicity$27$28,11326 claims
Boehringer IngelheimJardiance$21$11,19111 claims
GSKBreo Ellipta$50$9,78415 claims
AbbVieSynthroid$138$2,26320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 237 family medicine providers in Wyoming.

Other family medicine in Buffalo

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →